Open access
Oct 2026
Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma.
Not available.
Robert N. Stuver, Esther Drill, L. Michaud et al.
· Haematologica · 0 citations